Chewable Tablet Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Chewable tablet plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹4.9 crore - ₹86 crore CapEx this DPR captures:

• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance
• Plant Master File (PMF) and Site Master File (SMF) for export dossier
• NABL accreditation for QC lab, BSL-2/BSL-3 containment certification where applicable
• Bio-medical waste authorisation under BMW Rules 2016

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>The chewable tablet sector in India is segmented across vitamins and dietary supplements, antacids, analgesics, antihistamines, and other therapeutic categories. Globally, vitamins and dietary supplements command the largest segment share at 42.1 percent, followed by antacids at 18.2 percent, analgesics at 16.5 percent, antihistamines at 14.2 percent, and others at 9.0 percent. This segment distribution mirrors closely the Indian market structure where vitamins, minerals, and supplement chewables dominate production volumes.

The market is bifurcated between organized and unorganized manufacturing sectors: the organized sector comprises approximately 35 percent to 40 percent of the manufacturing landscape and consists of capital-intensive, automated plants compliant with WHO-GMP standards and regulatory requirements. The unorganized sector accounts for the remaining 60 percent to 65 percent, typically comprising smaller-scale operations with limited automation and regulatory adherence.</p><p>Demand drivers are robust and multi-faceted. Over 71.5 percent of consumers globally prefer chewable formulations over traditional tablets due to swallowing difficulties, known as dysphagia, or general pill fatigue.

Demographic trends strongly favor chewable formats: Gen Z and Millennials in the age group of 18 to 35 years drive 64.8 percent of the preference for non-pill formats such as chewables, gummies, and effervescent powders over conventional pills. The global wellness market reached USD 4.5 trillion in 2025, creating a massive tailwind for nutritional supplement demand including chewable tablets. Key demand verticals include pediatric and geriatric populations, both of whom face inherent swallowing challenges, as well as health-conscious adults seeking preventive care solutions.

India's broader consumer healthcare market has exceeded INR 40,000 crore, providing a deep domestic demand base for chewable tablet manufacturers.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Chewable tablet manufacturing employs a range of advanced production technologies, each suited to different formulation requirements and scale of operations. The primary manufacturing processes include direct compression, wet granulation, melt granulation, twin-screw continuous granulation, or TSG, foam granulation, and emerging technologies such as 3D printing and binder jetting. Direct compression technology offers significant operational advantages by eliminating thermal drying and wet granulation phases, thereby reducing thermal energy requirements in solid dose formulation.

Optimization of HVAC systems and dynamic cleanroom air-handling parameters can lower overall operational electricity intensity by 15 percent to 30 percent, making energy-efficient manufacturing a practical reality for modern chewable tablet plants.</p><p>The global tablet press machines market reached USD 1.6 billion in 2025 and is projected to grow to USD 2.6 billion by 2035, expanding at a CAGR of 5.3 percent from 2025 to 2035, reflecting sustained investment in tablet manufacturing infrastructure. Automation adoption is accelerating: fully automatic tablet press systems account for 49.0 percent of operational systems in the current market, signaling a decisive shift toward automated production lines. For chewable tablets specifically, critical quality parameters include tablet hardness, which must be maintained under 12 kiloponds, or kp, to ensure the tablet breaks down smoothly in saliva without causing dental damage.

Friability control is equally important, as softer formulation structures increase tablet fragility during handling and transport, requiring careful process design and packaging solutions.</p><p>India hosts a robust ecosystem of domestic plant and machinery manufacturers. Cadmach Machinery Co. Pvt.

Ltd., headquartered in Ahmedabad, Gujarat, specializes in tablet compression machinery and complete tableting lines. Karnavati Engineering Ltd., operating under the Rimek brand and located in Mehsana and Ahmedabad, Gujarat, produces high-speed rotary tablet presses and comprehensive pharmaceutical machinery lines. These domestic equipment manufacturers offer significant cost and logistical advantages over imported alternatives for new chewable tablet plant projects.</p><p>Unit economics in the chewable tablet sector are attractive.

Gross profit margins range from 40 percent to 50 percent, while net profit margins fall between 18 percent and 28 percent, according to IMARC Group data from 2026. Operating cost breakdown for nutraceutical and tablet plant operations allocates 45 percent to 55 percent for raw materials, 15 percent to 20 percent for labor, and 30 percent to 40 percent for utilities, maintenance, and other operating expenditures. Third-party tablet sourcing or manufacturing costs in certified Indian facilities located in hubs such as Baddi and Panchkula range from INR 0.80 to INR 2.50 per blister strip containing 10 tablets, or approximately INR 0.08 to INR 0.25 per individual tablet for standard production runs.</p>

For a chewable tablet plant project at ₹4.9 crore - ₹86 crore CapEx with a 3.6 - 5.4-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

<p>Chewable tablet manufacturing presents distinct technical and operational risks that require careful mitigation. The fundamental formulation challenge involves balancing mechanical strength against mouthfeel: chewable tablets require a low hardness profile, ideally maintained under 12 kiloponds, to ensure smooth breakdown in saliva without compromising dental health. Softer formulation structures inherently increase tablet fragility, leading to elevated friability and dust generation during handling, transport, and packaging.

Managing this hardness-friability trade-off requires sophisticated formulation expertise and precise process control, representing a significant technical barrier for new entrants without experienced formulation scientists and process engineers.</p><p>Raw material cost volatility poses a material risk to operating margins. Since raw materials constitute 45 percent to 55 percent of total operating costs for nutraceutical and tablet plant operations, fluctuations in the global APIs market and pharmaceutical excipients market directly impact profitability. The APIs market, valued at USD 255.01 billion in 2024 and growing at a CAGR of 5.85 percent through 2030, along with the pharmaceutical excipients market at USD 9.86 billion to USD 11.90 billion in 2026, are subject to supply chain disruptions, geopolitical factors, and commodity price cycles.

Domestic API import dependency creates additional foreign exchange and supply continuity risks for chewable tablet manufacturers reliant on imported active ingredients.</p><p>Regulatory compliance costs and risks are substantial. The mandatory requirements of WHO-GMP certification, Schedule M compliance under the Drugs and Cosmetics Rules, Form 25 and Form 28 licensing through CDSCO and State Licensing Authorities, and adherence to 21 CFR Part 111 and 21 CFR Part 211 for export markets impose significant ongoing compliance costs. Regulatory inspections, product recalls, and license suspension risks require sustained investment in quality assurance infrastructure and personnel.

The organized sector's regulatory compliance advantages over the unorganized sector create competitive pressure that smaller entrants may struggle to match without sufficient capital investment.</p><p>Competitive risks emanate from multiple directions. Gummy supplements, valued at USD 7.2 billion globally in 2022 and projected to reach USD 12.4 billion by 2031, represent a rapidly growing competing format with strong appeal among younger consumers. Domestic startups including Plix, founded in 2019, and Fast and Up are innovating aggressively in alternative oral formats, eroding the traditional chewable tablet market share.

The unorganized sector, comprising 60 percent to 65 percent of the manufacturing landscape, competes aggressively on price, creating margin compression risks for organized sector players. Globally, major players including Abbott Laboratories, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Sanofi S.A., Amway Corporation, and Johnson and Johnson wield significant brand equity, distribution reach, and R&D capabilities that create formidable barriers for new entrants seeking to compete on branded products.</p><p>Capital intensity represents a significant entry barrier. A small-scale domestic plant requires INR 5 crores to INR 15 crores in CapEx, while a mid-scale export-ready facility demands INR 50 crores to INR 80 crores.

The 18 percent GST applicable to pharmaceutical manufacturing plant machinery under HSN codes 8401 to 8487 adds to upfront costs. Although financing schemes such as PMMY provide support, the gap between available financing and required capital for a competitive mid-scale facility remains substantial. Additionally, the global tablet press machines market growth at a CAGR of 5.3 percent implies rising equipment costs over time, making timely investment critical.</p>